Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Macromolecular cytosolic delivery: Cell membranes as the primary obstacle

Abstract

The “evolution” of a thing, a custom, an organ is thus by no means its progressus toward a goal, even less a logical progressus by the shortest route and with the least expenditure of force, but a succession of more of less profound, mutually independent processes of subduing, plus the resistances they encounter, the attempts at transformation for the purpose of defense and reaction, and the results of successful counteractions. The form is fluid, but the “meaning” is even more so (Friedrich W. Nietzsche).

This is a preview of subscription content, log in to check access.

References Cited

  1. Anonymous.,Nature Biotechnology 16, 115 (1998)

  2. Barry, E., Gesek, F. and Friedman, P.,Biotechniques 15, 1016–1020 (1993)

  3. Bielecki, J, Youngman, P., Connelly, P. and Portnoy, D.,Nature 345(6271), 175–176 (1990).

  4. Blessing, T., Remy, J. S. and Behr, J. P.,Proc. Natl. Acad. Sci. USA 95, 1427–31 (1998).

  5. Bron, R., Ortiz, A. and Wilschut, J.,Biochemistry 33, 9110–9117 (1994).

  6. Brugge, J., Science 260, 918–919 (1993).

  7. Budker, V., Knorre, D. and Vlassov, V.,Antisense Res. Dev., 2. 177–184 (1992).

  8. Carter, B. J.,Nature Biotechnology 14, 1725–1726 (1996).

  9. Castanotto, D., Rossi, J. and Sarver, N.,Adv. Pharmacol. 25, 289–317 (1994).

  10. Cech, T., The Journal of the American Medical Association 260 3030–3034 (1988).

  11. Cossart, P., Vicente, M. F., Mengaud, J., Baquero, F., Perez-Diaz, J. C. and Berche, P.,Infection & Immunity 57, 3629–36 (1989).

  12. Courvalin, P., Coussard, S. and Grillot-Courvalin, C.,C. R. Acad. Sci. III 318 1207–1212 (1995).

  13. Crook, K., Stevenson, B. J., Dubouchet, M. and Porteous, D. J.,Gene Therapy 5, 137–143 (1998).

  14. Crooke, S.,Annu, Rev. Pharmacol. Toxicol. 32, 329–376 (1992).

  15. Crystal, R.,Science 270, 404–410 (1995).

  16. Curiel, D., inGene Therapeutics: Methods and applications of direct gene transfer (Wolff, J. ed), Birkhauser, Boston (1994).

  17. Curiel, D. T., Agarwal, S., Wagner, E. and Cotten, M.,Proc. Natl. Acad. Sci. USA 88, 8850–4 (1991).

  18. Darji, A., Chakraborty, T., Wehland, J. and Weiss, S.,Eur. J. Immunol. 27, 1353–1359 (1997).

  19. Darji, A., Guzman, C., Gerstel, B. Wachholz, P., Timmis, K., Wehland, J., Chakraborty, T. and Weiss, S.,Cell 91, 765–775 (1997).

  20. Dietrich, G., Bubert, A., Gentschev, I., Sokolovic, Z., Simm, A., Catic, A., Kaufmann, S., Hess, J., Szalay, A. and Goebel, W.,Nature Biotechnology 16, 181–185 (1998).

  21. Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., Ramsey, P., Martin, M. and Felgner, P. L.,J. Biol. Chem. 269, 2550–61 (1994).

  22. Felgner, P. L.,Laboratory Investigation 68, 1–3 (1993).

  23. Felgner, P. L. and Rhodes, G.,Nature 349(6307), 351–2 (1991).

  24. Felgner, P. L. and Ringold, G. M.,Nature 337 (6205), 387–8 (1989).

  25. Gao, X. and Huang, L.,Gene Therapy 2, 710–22 (1995).

  26. Gottschalk, S., Tweten, R., Smith, L. and Woo, S.,Gene Therapy 2, 498–503 (1995).

  27. Haensler, J. and Szoka, F. J.,Bioconjugate Chemistry 4, 372–9 (1993).

  28. Higgins, D. and Portnoy, D.,Nature Biotechnology 16, 138–139 (1998).

  29. Hong, K., Zheng, W., Baker, A. and Papahadjopoulos, D.,FEBS Letters 400, 233–7 (1997).

  30. Ikonomidis, G., Paterson, Y., Kos, F. J. and Portnoy, D. A.,J. Exp. Med. 180, 2209–18 (1994).

  31. Jones, S. and Portnoy, D. A.,Infection & Immunity 62, 5608–13 (1994).

  32. Kato, Y. and Sugiyama, Y.,Crit. Rev. in Therapeutic Drug Carrier Sys. 14, 287–331 (1997).

  33. Kim, J.-S., Maruyama, A., Akaike, T. and Kim, S. W.,Pharm. Res. 15(1), 116–121 (1998).

  34. Kling, J.,Nature Biotechnology 12 948 (1996).

  35. Kochanek, S., Clemens, P., Mitani, K., Chen, H.-H., Chan, S. and Caskey, C.,Proc. Natl. Acad. Sci. USA 93, 5731–5736 (1996).

  36. Langer, R.,Science 249, 1527–1533 (1990).

  37. Lasic, D. D. and Papahadjopoulos, D.,Science 267(5202), 1275–6 (1995).

  38. Lasic, D. and Martin, F., (eds)Stealth liposomes, CRC, Boca Raton, FL (1995).

  39. Ledley, F.,Human Gene Therapy 6, 1129–1144 (1995).

  40. Lee, K.-D., Oh, Y., Portnoy, D. and Swanson, J.,J. Biol. Chem. 271, 7249–7252 (1996).

  41. Lee, R. J. and Huang, L.,Crit. Rev. in Therapeutic Drug Carrier Sys 14, 173–206 (1997).

  42. Legendre, J. Y. and Szoka, F. J.,Pharm. Res. 9, 1235–42 (1992).

  43. Legendre, J. Y. and Szoka, F. J.,Proc. Natl. Acad. Sci. USA. 90, 893–7 (1993).

  44. Mulligan, R.,Science 260, 926–932 (1993).

  45. Papahadjopoulos, D.,J. of Liposome Research 5, 9–14 (1995).

  46. Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K.-D., Woodle, M. C., Lasic, D. D., Redemann, C. and Martin, F. J.,Proc. Natl. Acad. Sci. USA 88, 11460–11464 (1991).

  47. Plank, C., Oberhauser, B., Mechtler, K., Koch, C. and Wagner, E.,J. Biol. Chem. 269, 12918–24 (1994).

  48. Portnoy, D. A. and Jones, S.,Annals of the New York Academy of Sciences 730, 15–25 (1994).

  49. Portnoy, D. A., Tweten, R. K., Kehoe, M. and Bielecki, J.,Infection & Immunity 60, 2710–7 (1992).

  50. Portnoy, D., Jacks, P. and Hinrichs, D. J.,Exp. Med. 167, 1459–1471 (1988).

  51. Potts, R. and Chizmadzhev, Y.,Nature Biotechnology 16, 135 (1998).

  52. Poznansky, M. and Juliano, R.,Pharmacol. Rev. 36, 277–336 (1984).

  53. Robbins, P. D., Tahara, H. and Ghivizzani, S. C.,Trends in Biotechnology 16, 35–40 (1998).

  54. Sizemore, D., Branstrom, A. and Sadoff, J.,Science 270, 299–302 (1995).

  55. Tang, M. and Szoka, F.,Gene Therapy 4, 823–832 (1997).

  56. Tolstoshev, P.,Annual Review of Pharmacology and Toxicology 32, 573–596 (1993).

  57. Wagner, E., Plank, C., Zatloukal, K., cotten, M. and Birnstiel, M.,Proc. Natl. Acad. Sci. USA 89, 7934–7938 (1992).

  58. Wagner, E., Zatloukal, K., Cotten, M., Krilappos H., Mechtler, K., Curiel, D. and Birnstirl, M.,Proc. Natl. Acad. Sci. USA 89, 6099–6103 (1992).

  59. Wagner, R.,Nature Med. 1, 541–545 (1995).

  60. Wang, C. Y. and Huang, L.,Proc. Natl. Acad. Sci. USA 84, 7851–5 (1987).

  61. Wang, C.Y. and Huang, L.,Biochemistry 28, 9508–14 (1989).

  62. Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G. and Low, P. S.,Proc. Natl. Acad. Sci. USA 92, 3318–22 (1995).

  63. Wolff, J. A. and Lederberg, J.,Human Gene Therapy 5, 469–480 (1994).

  64. Woo, S. L. C.,Nature Biotechnology, 14, 1538 (1996).

  65. Wu, G. Y., Zhan, P., Sze, L. L., Rosenberg, A. R. and Wu, C. H.,J. Biol. Chem. 269, 11542–6 (1994).

  66. Wyman, T. B., Nicol, F., Zelphati, O., Scaria, P. V., Plank, C. and Szoka, F. C., Jr.,Biochemistry 36, 3008–17 (1997).

Download references

Author information

Correspondence to Kyung-Dall Lee.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Larson, G.M., Lee, K. Macromolecular cytosolic delivery: Cell membranes as the primary obstacle. Arch. Pharm. Res. 21, 621–628 (1998). https://doi.org/10.1007/BF02976747

Download citation

Key words

  • Cytosolic delivery
  • Cell membranes
  • Primary obstacle
  • Gene
  • Viral vector
  • Nonviral vector
  • Bacterial vector